PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT05732428
- Locations
- 🇨🇳
Jilin Province Tumor Hospital, Changchun, Jilin, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 58
- Registration Number
- NCT05732454
- Locations
- 🇺🇸
California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸Dr. Carolyn M. Wong, Los Angeles, California, United States
🇺🇸Dr. Gerald Markovitz, Los Angeles, California, United States
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT05733104
- Locations
- 🇰🇷
Pfizer, Seoul, Gangnam-gu, Korea, Republic of
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT05721937
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A GBT021601 ADME Microtracer Study in Healthy Volunteers
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT05718687
- Locations
- 🇳🇱
ICON Early Phase Clinic, LLC, Groningen, Netherlands
A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05712460
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)
- Conditions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1300
- Registration Number
- NCT05709158
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT05703607
- Locations
- 🇺🇸
Tri-City Cardiology, Gilbert, Arizona, United States
🇺🇸Aventiv Research Inc., Mesa, Arizona, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT05699135
- Locations
- 🇨🇦
Bayshore Specialty Rx, Mississauga, Ontario, Canada
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland